Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Small Cap Growth Fund”. You can download a copy of the letter here. Small-cap stocks delivered marginal gains in the fourth quarter of 2025. The Russell 2000® Value Index outperformed the Russell 2000® Growth Index in the quarter, with more balanced results. In line with the broader stock market, small-cap stocks delivered solid results in 2025. The Russell 2000 Growth Index returned 13.01%, outperforming the Russell 2000 Value Index’s 12.58% gain. The firm anticipates a favorable year ahead for equity markets. The letter outlined the potential opportunities within Cyclicals, Healthcare, Information Technology, Financials, and Consumer spending sectors heading to 2026. Please review the Fund’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, the Carillon Eagle Small Cap Growth Fund highlighted Guardant Health, Inc. (NASDAQ:GH) as one of its leading contributors. Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company that provides in blood and tissue tests and data sets. On February 13, 2026, Guardant Health, Inc. (NASDAQ:GH) stock closed at $104.85 per share. One-month return of Guardant Health, Inc. (NASDAQ:GH) was -6.50%, and its shares are up 117.89% over the past twelve months. Guardant Health, Inc. (NASDAQ:GH) has a market capitalization of $13.617 billion.
Carillon Eagle Small Cap Growth Fund stated the following regarding Guardant Health, Inc. (NASDAQ:GH) in its fourth quarter 2025 investor letter:
“Guardant Health, Inc. (NASDAQ:GH) is a pioneer in a new field of clinical diagnostic testing known as liquid biopsy. This technology enables highly sensitive cancer detection from blood samples and supports applications such as therapy selection, disease monitoring, and multi cancer screening, including for colorectal cancer. The company estimates that the total addressable market is substantial and has recently reported strong financial performance. Strategic progress includes submissions to the U.S. Food and Drug Administration (FDA), expanded reimbursement coverage, and margin improvements that could position Guardant to achieve cash flow breakeven ahead of schedule.”
Guardant Health, Inc. (NASDAQ:GH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 50 hedge fund portfolios held Guardant Health, Inc. (NASDAQ:GH) at the end of the third quarter, up from 46 in the previous quarter. While we acknowledge the potential of Guardant Health, Inc. (NASDAQ:GH) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
